Healthy Controls Group - Age and Sex-matched, Patients With Heart Failure and Preserved Ejection Fraction - HFpEF, Patients With Heart Failure With Reduced Ejection Fraction - HFrEF
Conditions
Keywords
HFpEF, HFrEF
Brief summary
The investigators wish to test a hypothesis that patients with HFpEF have different characteristics on echo, cardiac MRI and plasma protein & chemical profiles compared to HFrEF and healthy volunteers.
Detailed description
Large scale prospective studies incorporating cardiac MRI, echocardiography and plasma sampling are currently lacking in HFpEF. The main aims of our study are to: 1. better phenotype and characterise HFpEF (also comparing with HFrEF and age- and sex- matched healthy controls) 2. provide mechanistic insights into pathophysiology 3. describe potential biomarkers and their relation to relevant clinical outcomes (exercise capacity, heart failure quality of life and prognosis)
Interventions
DIAGNOSTIC_TESTMRI scan, Echo scan
Sponsors
National Institute for Health Research, United Kingdom
University of Leicester
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Clinical features of heart failure or prior radiographic evidence in the absence of symptoms And Either ejection fraction \> 50% (for HFpEF arm) or ejection fraction \< 40% (for HFrEF arm)
Exclusion criteria
* Myocardial infarction within the preceding 6 months * Suspected or confirmed cardiomyopathy (e.g. hypertrophic, infiltrative) * Suspected or confirmed constrictive pericarditis * Significant native valve disease (≥ moderate severity) * Known Significant lung disease (documented or FEV1\< 30% or FVC \< 50%) * Non-cardiovascular co-morbidity likely to cause death within 6 months (e.g. malignancy) * Significant renal failure (estimated GFR \< 30 ml/min/m2) * Patient inability to provide informed consent (e.g. dementia)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The composite end-point of all-cause mortality or repeat hospitalisation with heart failure | Minimum 6 month follow-up |
Secondary
| Measure | Time frame |
|---|---|
| The number of new clinical diagnoses detected by cardiac MRI | Through study completion, an average of 1 year |
| Exercise capacity as assessed by the six-minute walk test | Through study completion, an average of 1 year |
| Quality of life assessed by the Minnesota Living with Heart Failure Questionnaire | Through study completion, an average of 1 year |
Outcome results
None listed